PHAT NASDAQ
Credit Risk of going bust: higher than 75% of companies Debt: 25.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.25 (down 96%), Phathom Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $167.1M against a stock market value of $480.6M.
Distance to default 3.05 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $82.3M (short-term plus half of long-term), stock volatility 68.3%; Altman Z'' -13.69. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Florham Park, NJ 07932
US
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Narula Sanjeev | F-InKind | 13,485 | $6.78 | 2026-10-06 |
| Breedlove Robert Cha | F-InKind | 460 | $9.05 | 2026-09-03 |
| Breedlove Robert Cha | F-InKind | 1,555 | $11.04 | 2026-07-14 |
| Parikh Asit | G-Gift | 28,000 | — | 2026-05-22 |
| Parikh Asit | G-Gift | 28,000 | — | 2026-05-22 |